Recombinant Human MET/c-Met/HGFR Protein, N-His (PX-P5755)
概述
图片
参考文献
概述
货号
PX-P5755
品牌
ProteoGenix
描述
Recombinant Human MET/c-Met/HGFR Protein, N-His (PX-P5755) expressed in E. coli, Purity: >90% as determined by SDS-PAGE..
Highlights
High Purity (>90% as determined by SDS-PAGE.) — Verified by SDS-PAGE for downstream accuracy.
E. coli Expression — Optimized for functional studies.
表达系统
E. coli
Accession号
P08581
蛋白长度
Val1092-Val1379
应用
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
种属
Homo sapiens (Human)
性质
Recombinant
内毒素水平
Please contact with the lab for this information.
纯度
>90% as determined by SDS-PAGE.
预测分子量
35.05 kDa
状态
Lyophilized
保存溶液
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
重悬
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
运输
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
稳定性和存储
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Hepatocyte growth factor receptor (MET/HGFR) is a ~155 kDa protein. Receptor tyrosine kinase that transduces signals from the extracellular matrix into the cytoplasm by binding to hepatocyte growth factor/HGF ligand. Regulates many physiological processes including proliferation, scattering, morphogenesis and survival. Ligand binding at the cell surface induces autophosphorylation of MET on its intracellular domain that provides docking sites for downstream signaling molecules. Following activation by ligand, interacts with the PI3-kinase subunit PIK3R1, PLCG1, SRC, GRB2, STAT3 or the adapter GAB1. Recruitment of these downstream effectors by MET leads to the activation of several signaling cascades including the RAS-ERK, PI3 kinase-AKT, or PLCgamma-PKC. MET is the therapeutic target of amivantamab (Rybrevant).
